| Source: HalifaxProj (inhibit) |
| Type: |
| A signal protein produced by many cells that stimulates the formation of blood vessels.
Vascular endothelial growth factor (VEGF) is a signal protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. This process is vital for normal physiological functions, such as wound healing and the menstrual cycle, but it is also a key factor in the growth and spread of tumors in cancer. Because of its significant role in tumor growth and progression, VEGF has become a target for cancer therapies. Anti-VEGF therapies, such as monoclonal antibodies (e.g., bevacizumab) and small molecule inhibitors, aim to inhibit the action of VEGF, thereby reducing blood supply to tumors and limiting their growth. These therapies have been used in various types of cancer, including colorectal, lung, and breast cancer. |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2824- | FIS, | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
| - | Review, | Var, | NA |
| 2827- | FIS, | The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 6912- | FIS, | Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers |
| - | Review, | Var, | NA |
| 6978- | Form, | Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway |
| - | vitro+vivo, | Nor, | HUVECs |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6986- | Form, | Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway |
| - | in-vitro, | NA, | NA |
| 6967- | Form, | BTZ, | Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model |
| - | in-vivo, | Melanoma, | U266 | - | in-vivo, | Melanoma, | RPMI-8226 |
| 7005- | Fuc, | Fucoidan and cancer: a multifunctional molecule with anti-tumor potential |
| - | Review, | Var, | NA |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 7008- | Fuc, | Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects |
| - | Review, | Var, | NA |
| 948- | Fuc, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24/HTB-9 | - | in-vitro, | Nor, | HUVECs |
| 1114- | Fuc, | The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study |
| - | vitro+vivo, | NA, | NA |
| 1155- | Fuc, | The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations |
| - | Review, | NA, | NA |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 7033- | GA, | OL, | Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line |
| - | in-vitro, | OS, | U2OS |
| 7065- | GamB, | Gambogic acid: A review of its pharmacological mechanisms against cancer |
| - | Review, | Var, | NA |
| 7060- | GamB, | New targets for the antitumor activity of gambogic acid in hematologic malignancies |
| - | Review, | Melanoma, | RPMI-8226 |
| 7067- | GamB, | Gambogic Acid and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 5148- | GamB, | Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics |
| - | Review, | Var, | NA |
| 5150- | GamB, | Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway |
| - | in-vitro, | CLL, | KBM-5 | - | in-vitro, | Nor, | HEK293 |
| 7088- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC4 |
| 7086- | GAR, | Garcinol: An emerging epigenetic modifier with versatile anticancer properties |
| - | Review, | Var, | NA |
| 7089- | GAR, | Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | PC, | NA |
| 7092- | GAR, | Garcinol and Its Role in Chronic Diseases |
| - | Review, | Var, | NA |
| 811- | GAR, | Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 810- | GAR, | GEM, | Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures |
| - | in-vitro, | PC, | NA |
| 805- | GAR, | Cisplatin, | PacT, | Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells |
| - | Review, | NA, | NA |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 793- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC9 | - | in-vitro, | SCC, | SCC4 | - | in-vitro, | SCC, | SCC25 |
| 7102- | GEN, | Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits |
| - | Review, | Var, | NA |
| 2998- | GEN, | Cellular and Molecular Mechanisms Modulated by Genistein in Cancer |
| - | Review, | Var, | NA |
| 7199- | GGB, | Ginkgolide B Promotes Angiogenesis After Oxygen-Glucose Deprivation by Regulating AKT1 in bEnd.3 Cells |
| - | in-vitro, | Stroke, | NA |
| - | Review, | Var, | NA |
| 7288- | GGB, | Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1005- | GI, | Ginger Constituent 6-Shogaol Inhibits Inflammation- and Angiogenesis-Related Cell Functions in Primary Human Endothelial Cells |
| - | vitro+vivo, | Nor, | HUVECs |
| 1116- | GI, | 6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway |
| - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | CRC, | HCT116 |
| 7249- | Gink, | RES, | Synergy of Ginkgetin and Resveratrol in Suppressing VEGF-Induced Angiogenesis: A Therapy in Treating Colorectal Cancer |
| - | vitro+vivo, | NA, | NA |
| 4243- | Gins, | Effects of Ginseng on Neurological Disorders |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 4505- | GLA, | Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α |
| - | in-vitro, | NSCLC, | Calu-1 |
| 7321- | Gos, | The potential roles of gossypol as anticancer agent: advances and future directions |
| - | Review, | Var, | NA |
| 7311- | Gos, | Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials |
| - | Review, | CLL, | NA |
| 850- | Gra, | Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin |
| - | in-vitro, | PC, | PC3 | - | in-vitro, | Pca, | DU145 |
| 1241- | GSE, | PACs, | Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling |
| - | in-vitro, | Nor, | NA |
| 7489- | H2, | Molecular Hydrogen in the Treatment of Respiratory Diseases |
| - | Review, | Asthma, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:334 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid